US Nuclear & Grapheton Provide Significant Advances for Parkinson’s Disease Therapy

Los Angeles, CA.  March 17, 2020 – The next chapter in US Nuclear’s (OTC: UCLE) brain-machine interface revolution in treating Parkinson’s Disease. Over 10 million people live with Parkinson’s Disease worldwide.  Parkinson’s Disease is a degenerative, progressive nervous system disorder that affects nerve cells in deep parts of the brain that control movement and memory. These nerve cells become impaired and/or die, thereby producing less dopamine thus ultimately causing the symptoms of Parkinson’s Disease. These symptoms include: tremors or shaking in your limbs, slowed movement, rigid muscles, impaired balance, coordination, and eventually, profound memory loss and dementia. Fortunately, advances in neurostimulation therapy, such as those made by Grapheton, have made it possible to treat this terrible disease.

The treatment is called ‘Deep Brain Stimulation (DBS) and involves the surgical implantation of electrodes in your brain that send electrical signals to the areas responsible for body movement. The electrodes do not damage healthy brain tissue or destroy nerve cells; instead, they produce electrical impulses that regulate the abnormal impulses, including those caused by Parkinson’s.

(more…)